EuroBiotech: More Articles of Note


> PolyProx Therapeutics, a University of Cambridge spinout, raised £3.4 million ($4.4 million) to work on drugs that engage cellular degradation machinery to stop tumor growth. Release

> 4D Pharma completed an early part of its phase 1/2 Keytruda combination trial without seeing dose-limiting toxicities. Statement 

> Freeline Therapeutics struck a multi-year agreement with Brammer Bio to secure access to gene therapy production capacity in the U.S. The capacity will support potential commercial demand for hemophilia B gene therapy FLT180a. Release


De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost.

> Baylor College of Medicine presented data on its Cell Medica-partnered GD2-CAR NKT cells. One of two patients treated with the lowest dose of the drug experienced “extensive tumor regression at four weeks.” Statement

> Amal Therapeutics teamed up with Boehringer Ingelheim to test its ATP128 in combination with anti-PD-1 antibody BI754091. Release

> Numab offloaded the Chinese rights to a trispecific antibody-based molecule targeting PD-L1, 4-1BB and human serum albumin to CStone Pharmaceuticals. Statement 

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.